Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 6/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012144 | 1.00 | SRD5A1 (0.61) | SRD5A1SRD5A2PSEN1PSEN2APH1B | |
| SCHEMBL14214561 | 1.00 | SRD5A1 (0.61) | SRD5A1SRD5A2PSEN1PSEN2APH1B | |
| SCHEMBL14184971 | 1.00 | SRD5A1 (0.61) | SRD5A1SRD5A2PSEN1PSEN2APH1B | |
| SCHEMBL9022079 | 0.89 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL9022075 | 0.89 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL29059721 | 0.89 | SRD5A1 (0.64) | SRD5A1 | |
| SCHEMBL11416876 | 0.89 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL5218487 | 0.89 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL14359701 | 0.88 | SRD5A2 (0.53) | SRD5A1SRD5A2PSEN1PSEN2APH1B | |
| SCHEMBL8707080 | 0.85 | SRD5A2 (0.65) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1734964-A4 | 17 BETA-ACETAMIDE-4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | disclosed |
| EP-1734964-A1 | 17 BETA-ACETAMIDE-4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-14 | — | — | US | disclosed |
| WO-2005099707-A1 | 17 BETA-ACETAMIDE-4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | WANG JIABING (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1501512-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092588-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | NR5A1, AR, NR3C1 | SRD5A1 5/4885SRD5A2 9/4885PSEN1 1490/4885 |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | AR, NR5A1, NR3C1 | SRD5A1 5/4885SRD5A2 9/4885PSEN1 1402/4885 |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | AR, CYP17A1, SHBG | SRD5A1 18/4885SRD5A2 20/4885PSEN1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.